ArticleInternational journal of nanomedicine2018
Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 66 citations in OpenAlex.
- Selenium Nanoparticles Synergize with a KRAS Nanovaccine against Breast Cancer.Advanced healthcare materials · 2025Article
- Selenium nanoparticle-delivered MDM2 inhibitor reactivates p53 and reprograms tumor immune microenvironment in colorectal cancer.Frontiers in immunology · 2025Article
- Biosynthesis of selenium nanoparticles as a potential therapeutic agent in breast cancer: G2/M arrest and apoptosis induction.Toxicology reports · 2024Article
- Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects.Scientific reports · 2023Article
- Pharmacological Prospects of Morin Conjugated Selenium Nanoparticles-Evaluation of Antimicrobial, Antioxidant, Thrombolytic, and Anticancer Activities.BioNanoScience · 2023Article
- Allotropy of selenium nanoparticles: Colourful transition, synthesis, and biotechnological applications.Microbial biotechnology · 2023Review
- Metal-based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy.MedComm · 2023Review
- Theranostic applications of selenium nanomedicines against lung cancer.Journal of nanobiotechnology · 2023Review
- Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model.Marine drugs · 2022Article
- Review
- Surface Engineering of Nanomaterials with Polymers, Biomolecules, and Small Ligands for Nanomedicine.Materials (Basel, Switzerland) · 2022Review
- The emergence of nanoporous materials in lung cancer therapy.Science and technology of advanced materials · 2022Review
- Immunomodulatory roles of selenium nanoparticles: Novel arts for potential immunotherapy strategy development.Frontiers in immunology · 2022Review
- Multicomponent siRNA/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy.Frontiers in bioengineering and biotechnology · 2022Article
- Smart Nanotherapeutics and Lung Cancer.Pharmaceutics · 2021Review
- Therapeutic Potential and Main Methods of Obtaining Selenium Nanoparticles.International journal of molecular sciences · 2021Review
- Advanced Nanoparticle-Based Drug Delivery Systems and Their Cellular Evaluation for Non-Small Cell Lung Cancer Treatment.Cancers · 2021Review
- The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications.Molecules (Basel, Switzerland) · 2021Review
- Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma.Bioactive materials · 2021Article
- An improved method in fabrication of smart dual-responsive nanogels for controlled release of doxorubicin and curcumin in HT-29 colon cancer cells.Journal of nanobiotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelenium nanoparticles (SeNPs) loaded with chemotherapeutic drugs provided a novel perspective for cancer therapy. MATERIALS AND
methodsHere, SeNPs were modified with cyclic peptide (Arg-Gly-Asp-d-Phe-Cys [RGDfC]) to fabricate tumor-targeting delivery carrier RGDfC-SeNPs and, then, doxorubicin (DOX) was loaded to the surface of RGDfC-SeNPs for improving the antitumor efficacy of DOX in non-small-cell lung carcinoma therapy.
resultsThe chemical structure characterization of RGDfC-Se@DOX showed that DOX was successfully loaded to the surface of RGDfC-SeNPs to prepare functionalized antitumor drug delivery system RGDfC-Se@DOX. RGDfC-Se@DOX exhibited effective cellular uptake in A549 cells and entered A549 cells mainly by clathrin-mediated endocytosis pathway. Compared to free DOX or Se@DOX at the equivalent dose of DOX, RGDfC-Se@DOX showed greater activity to inhibit A549 cells' proliferation and migration/invasion and induce A549 cells' apoptosis. More importantly, compared with passive targeting delivery system Se@DOX, active targeting delivery system RGDfC-Se@DOX exhibited more significant antitumor efficacy in vivo.
conclusionTaken together, RGDfC-Se@DOX may be a novel promising drug candidate for the lung carcinoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.